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Plasma transferrin and hemopexin are
associated with altered Aβ uptake and
cognitive decline in Alzheimer’s disease
pathology
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Jurgen Fripp12, David Ames13,14, Christopher Rowe15, Colin L. Masters16, Victor Villemagne15, Abdul Hye2,3†,
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Abstract
Background: Heme and iron homeostasis is perturbed in Alzheimer’s disease (AD); therefore, the aim of the study
was to examine the levels and association of heme with iron-binding plasma proteins in cognitively normal (CN),
mild cognitive impairment (MCI), and AD individuals from the Australian Imaging, Biomarker and Lifestyle Flagship
Study of Ageing (AIBL) and Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohorts.
Methods: Non-targeted proteomic analysis by high-resolution mass spectrometry was performed to quantify relative
protein abundances in plasma samples from 144 CN individuals from the AIBL and 94 CN from KARVIAH cohorts and
21 MCI and 25 AD from AIBL cohort. ANCOVA models were utilized to assess the differences in plasma proteins
implicated in heme/iron metabolism, while multiple regression modeling (and partial correlation) was performed to
examine the association between heme and iron proteins, structural neuroimaging, and cognitive measures.
Results: Of the plasma proteins implicated in iron and heme metabolism, hemoglobin subunit β (p= 0.001) was significantly
increased in AD compared to CN individuals. Multiple regression modeling adjusted for age, sex, APOEε4 genotype, and
disease status in the AIBL cohort revealed lower levels of transferrin but higher levels of hemopexin associated with augmented
brain amyloid deposition. Meanwhile, transferrin was positively associated with hippocampal volume and MMSE performance,
and hemopexin was negatively associated with CDR scores. Partial correlation analysis revealed lack of significant associations
between heme/iron proteins in the CN individuals progressing to cognitive impairment.
Conclusions: In conclusion, heme and iron dyshomeostasis appears to be a feature of AD. The causal relationship between
heme/iron metabolism and AD warrants further investigation.
Keywords: Alzheimer’s disease, Cognitively normal, Cognitive impairment, Heme, Hemoglobin, Iron, Mild cognitive impairment,
Proteomics, Transferrin
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Background
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly population, with an estimated
prevalence of 115.4 million cases by 2050 [1]. AD is a
heterogenous disorder characterized clinically by
apraxia, aphasia, and agnosia and neuropathologically by
the presence of β-amyloid plaques and hyperphosphory-
lated tau tangles [2, 3]. Regional measures of hippocam-
pal atrophy have been identified as strong predictors of
progression to AD [4]. Emerging evidence suggests that
brain and blood iron homeostasis is perturbed in AD,
with studies showing decreased peripheral iron (anemia)
and lower hemoglobin levels [5–11]. Anemia is a preva-
lent condition in the elderly and is associated with an in-
creased risk of acquiring AD [7, 8, 12, 13].
Evidence suggests that hemoglobin (Hb), a group of
iron-containing heme proteins, is not exclusively re-
stricted to the blood but likely play a role in pathophysi-
ology of the brain and neurodegenerative diseases [14].
Hb acts likely as an oxygen storage molecule to counteract
hypoxic effects on neurons, which have high obligate de-
mand for sustained energy [14, 15]. Hb is expressed
throughout the brain including the striatum, corpus callo-
sum, and brainstem [14, 15]. High levels of Hb compo-
nents are evident in brains of older humans and rats [16],
associated with impaired learning and memory [17]. Hb
interacts with β-amyloid (Aß) and co-localizes with Aß
plaques in AD post-mortem brains [18, 19]. Importantly,
Hb levels were augmented in amyloid pathology-
associated brain regions—inferior temporal gyrus, cerebral
parietal gray matter, and parietal white matter [19]. The
association between brain region-specific Hb levels and
Aβ pathology in AD patients suggests a link between Hb
expression and AD pathogenesis.
Although research evaluating the differences between
individual subunits of Hb remains sparse, there is evi-
dence that specific subunits have varying properties and
functions. Studies of blood from healthy humans show
that Hbα subunits efficiently scavenge hydrogen perox-
ide to prevent oxidative degradation of Hb [20]. Hbα-
positive neurons, juxtaposing Hbα-negative neurons,
have higher oxygenation potential in hypoxic areas in
the mouse brain under normoxic and hypoxic conditions
[21]. Interestingly, Hbα levels were predominantly de-
creased in brain synaptosomes in a transgenic rat model
of AD [22]. Meanwhile, Hbβ-enriched neurons are fre-
quent in internal cortical layers IV–VI relative to exter-
nal layers I–III; most of these neurons had pyramidal
morphology with large size, apical dendrites, and long
axons [23]. It was found that overexpression of Hbβ but
not Hbα epigenetically increased histone H3 methylation
to sequester oxygen from histone demethylases [23]. Al-
though the α and β subunits of Hb function as a hetero-
tetramer in erythrocytes, these proteins have putatively
evolved specialized functions and may act independent
of one another in selected cells. This proposition is fur-
ther supported by the expression of Hbα in vascular
endothelial cells where it regulates nitric oxide signaling,
independent of Hbβ [24].
In neurons laden with hyperphosphorylated tau de-
posits, appreciable decreases in Hb subunits α and β were
evident in the frontal cortex and hippocampus in AD [25].
Analysis of samples from the CSF showed higher Hbα and
Hbβ which could differentiate between AD converters
from non-converters in individuals with mild cognitive
impairment (MCI) [26]. However, Hb subunits did not
yield significant differences between CN, MCI, and AD.
This suggests that Hb subunits may show an initial in-
crease in response to AD pathology but due to ongoing
disease, Hb may leak from degenerating neurons into CSF
and explain the augmented CSF levels in MCI converting
to AD. Note that a stringent protocol was implemented to
avoid blood contamination to ensure removal of plasma
proteins from CSF samples to assure robustness of results
[26]. The role of another Hb subunit, Hbδ, in aging and
disease has not been investigated. Hbδ genes show hom-
ology to Hbβ [15]; hence, it can be hypothesized to follow
similar changes to Hbβ in the context of AD.
Hb oxidation liberates free heme, a source of redox-
active iron, which produces reactive oxygen species
through Fenton reaction, inducing lipid peroxidation
[27]. This toxicity is modulated by hemopexin (HPX)
and haptoglobin, proteins which bind heme with high af-
finity to maintain iron homeostasis through recycling of
heme iron [28, 29]. Proteomics studies demonstrated in-
creased plasma and CSF HPX in AD patients compared
to cognitively normal (CN) subjects, suggesting impaired
compensation in neurodegeneration [30, 31]. It appears
that surplus contribution to heme by breakdown of Hb
may overwhelm the capacity of the heme scavenging sys-
tem in AD [28, 32–34].
Systemic deficits in iron trafficking can contribute to
morbidity associated with AD, since iron acts as a cata-
lyst for a plethora of metabolic processes, including
heme formation, neurotransmitter synthesis, and axonal
myelination [7, 8]. Deficiency of iron loading onto its
major transporter protein, transferrin, was observed in
AD [8], which suggests further examination of peripheral
iron/heme metabolism.
Since AD represents a global disease burden, plasma
proteins have been extensively associated with progres-
sion of the disease [35]. The present study investigated
the levels of plasma proteins involved in heme and iron
homeostasis in cognitively normal (CN), MCI, and AD
individuals. The uniqueness of the study was that it
identified CN individuals who either remained stable or
showed progression to cognitive impairment and exam-
ined retrospectively their baseline plasma proteins and
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association to AD markers. The baseline expression
levels of plasma hemoglobin (Hb) subunits (α, β, and δ)
and their association to AD markers have not been pre-
viously documented, highlighting the importance of the
present study. Based on the evidence reviewed, we
hypothesize that Hbβ would be associated with higher
Aβ deposition, hippocampal atrophy, and cognitive de-
cline. We also predict that higher levels of Hbα, hemo-
pexin, and transferrin will be associated with lower Aβ
deposition, improved hippocampal volumes, and im-
proved cognitive performance.
Methods
Participants
The dataset comprised 144 CN, 21 MCI, and 25 AD in-
dividuals derived from the Australian Imaging, Bio-
marker and Lifestyle Flagship Study of Ageing (AIBL
[11, 36, 37]) and 94 CN from Kerr Anglican Retirement
Village Initiative in Ageing Health (KARVIAH) cohort
[38]. The AIBL cohort underwent baseline Aβ PET im-
aging (11C-PIB) [37], while KARVIAH cohort had base-
line 18F-FBB (florbetaben) amyloid PET imaging [11].
Only the AIBL individuals included in the study received
magnetic resonance imaging (MRI) using the ADNI
three-dimensional magnetization prepared rapid gradi-
ent echo (MPRAGE) sequence, with the following pa-
rameters: 1 × 1 mm in-plane resolution, 1.2 mm slice
thickness, field of view 240 × 256, 160 slices, repetition
time (TR) = 2300ms, echo time (TE) = 2.98 ms, inversion
time (TI) = 900 ms, and flip angle 9°. T2-weighted fast
spin echo (FSE) and fluid attenuation inversion recovery
(FLAIR) sequences were also applied [37]. MRI-based
measures of hippocampal, gray matter, and white matter
volumes were derived.
AIBL and KARVIAH subjects had mini-mental state
examination (MMSE) [11, 37], while clinical dementia
rating scale (CDR) and sum of boxes (CDR SB) were
computed for the AIBL cohort [37].
Inclusion and exclusion criteria for KARVIAH
Participants with good health and no history of signifi-
cant cerebral vascular disease, fluent in English, with ad-
equate vision and hearing to enable testing, and with
normal general cognitive function as determined by
Montreal Cognitive Assessment (MoCA) [39] scores
greater than or equal to 26 were included. The exclusion
criteria included diagnosis of dementia based on the re-
vised criteria from the National Institute on Aging - Alz-
heimer’s Association, presence of acute functional
psychiatric disorder (including lifetime history of schizo-
phrenia or bipolar disorder), history of stroke, and pre-
senting with depression based on the Depression,
Anxiety, Stress Scales (DASS) and uncontrolled hyper-
tension (systolic BP > 170 or diastolic BP > 100).
Inclusion and exclusion criteria for AIBL
CN individuals were free of cognitive impairment, while
MCI was defined as a clinical syndrome characterized by
reduced cognitive performance (often involving mem-
ory), representing a risk state for development of frank
AD [40, 41]. The diagnosis of AD was made according
to the National Institute of Neurological and Communi-
cative Disorders and Stroke - Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) cri-
teria [42]. Allocation of individuals to CN, MCI, or AD
was undertaken by a clinical review panel (see below).
When individuals presented with an existing diagnosis
of MCI or AD, the diagnosis was established by a clinical
review panel to ensure that diagnoses were made ac-
cording to internationally agreed criteria. Potential par-
ticipants were excluded if they had a history of non-AD
dementia, schizophrenia, bipolar disorder, significant de-
pression (GDS score > 5/15), Parkinson’s disease, cancer
within last 2 years, stroke, or uncontrolled diabetes.
Dementia severity was rated for all participants with
CDR = 0, 0.5, 1, 2, or 3 when dementia is absent, ques-
tionable, mild, moderate, or severe, respectively [43].
Since six domain scores ranging from 0 to 3 are gener-
ated for CDR, a sum of boxes score is also calculated
ranging from 0 to 18.
Individuals that participated as CN at baseline in the
AIBL trial were discussed by a clinical review panel (com-
prising neurologists, old age psychiatrists, geriatricians,
and neuropsychologists). For individuals with an MMSE
score < 28, failure on the logical memory test (as per
ADNI guidelines, http://adni.loni.usc.edu/), and/or a CDR
score ≥ 0.5 [36], a consensus diagnosis was assigned based
on diagnostic criteria DSM-IV [44] and ICD-10 [45] and
whether the subject violated the exclusion criteria. CN in-
dividuals who progressed to fulfill MCI diagnosis accord-
ing to established Winblad et al. [41] and Petersen et al.
criteria [40] had to also have impairment on two or more
cognitive tests at a level of at least 1.5 standard deviation
below age-adjusted mean, in addition to have reported
memory difficulties. Individuals were assigned a diagnosis
of probable AD if they reported deficits in multiple cogni-
tive domains and impairment in activities of daily living
sufficient to satisfy NINCDS-ADRDA [42], DSM-IV [44],
and ICD-10 [45] criteria.
Mass spectrometry analysis
The methodology used in this study has been previously
described [38]. In brief, AIBL and KARVIAH plasma
samples were immuno-depleted of albumin and IgG,
and then enzymatically digested prior to tandem mass
tag (TMT) labeling. The resulting peptides were sepa-
rated into 24-fractions by an OFFGEL Fractionator (Agi-
lent Technologies) and individually analyzed by a Linear
Trap Quadrupole (LTQ) Orbitrap Velos Pro (Thermo
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Fisher Scientific), enabling chromatographic separation
and mass spectra acquisition.
Statistical analyses
Proteins involved in iron and heme metabolism were se-
lected from a panel of plasma proteins [38] and analyzed,
which included transferrin, ceruloplasmin, hemopexin,
haptoglobin, haptoglobin-related protein (HPR), Hb sub-
units (α, β, δ), cluster of differentiation 163 (CD163), and
low-density lipoprotein receptor-related protein (LRP1).
ANCOVA models were used to compare the baseline
levels of plasma proteins, neuroimaging, and cognition
measures between the diagnostic groups (CN, MCI, and
AD), adjusted for age, sex, APOEε4 genotype, and disease
status. Multiple regression models were utilized to study
the association of plasma proteins with neuroimaging
measures and cognitive assessments, where minimal
models were obtained using backward elimination.
Subsequently, the CN subset from the AIBL cohort
was dichotomized into individuals that progressed to
show symptoms of cognitive impairment and individuals
that remained stable, 6 years later. ANCOVA and linear
regression analysis was performed as described above
but the models were adjusted for age, sex, APOEε4
genotype, and conversion status. To delineate the associ-
ation of proteins involved in iron and heme metabolism,
partial correlation analysis was executed, adjusting for
age, sex, and APOEε4 genotype in CN individuals who
remained stable and in individuals progressing to cogni-
tive impairment.
To correct for multiple comparisons, we used an adap-
tive linear set-up procedure proposed by Benjamini et al.
[46] to control the false discovery rate (FDR) at 5%
across all the analyses. An FDR-corrected p value ≤
0.0167 was considered significant. All statistical analyses
were performed using IBM SPSS Statistics 24 and
GraphPad Prism 8.4.2.
Results
Baseline levels of plasma heme and iron proteins in CN,
MCI, and AD
The baseline demographic and clinical characteristics of
the different diagnostic groups are presented in Table 1.
AD subjects exhibited increased brain amyloid depos-
ition compared to CN and MCI, while MCI had higher
brain amyloid deposition than CN (p = 3.224 × 10−20).
The right (p = 0.008) and left hippocampal (p = 3.600 ×
10−5) volumes were found to be markedly reduced in
AD relative to CN. Individuals with AD had lower
MMSE scores and increased CDR and sum of boxes
compared to CN and MCI, while the MCI group per-
formed worse on MMSE (p = 9.453 × 10−54) and had
higher CDR (p = 9.139 × 10−56) and sum of boxes (p =
3.384 × 10−73) compared to CN.
Of the plasma proteins implicated in iron and heme me-
tabolism, Hbβ subunit (p= 0.001) was significantly increased
at baseline in AD compared to CN individuals (Table 2).
Relationship between baseline plasma proteins and
neuroimaging/cognitive measures in CN, MCI, and AD
Multiple regression modeling of brain amyloid depos-
ition (assessed by PET) revealed lower levels of transfer-
rin (β = − 0.206, p = 0.008) and a trend of lower Hbα
(β = − 0.194, p = 0.060, not significant), but higher HPX
levels (β = 0.215, p = 0.007) and a trend of increased Hbδ
(β = 0.186, p = 0.073, not significant) were associated
with augmented brain amyloid deposition (Fig. 1a).
Higher levels of transferrin were associated with larger
gray matter volume (β = 0.178, p = 0.005; Fig. 1b) and
non-significant improvements in MMSE scores (β =
0.077, p = 0.097; Fig. 1c). Higher levels of hemopexin
were associated with lower CDR scores that failed to
reach significance (β = − 0.064, p = 0.081; Fig. 1d).
Baseline levels of brain amyloid deposition, cognition,
and plasma proteins in CN individuals
CN individuals from the AIBL cohort stratified according
to their conversion status (Table 3) demonstrated elevated
brain amyloid deposition in individuals exhibiting progres-
sion to cognitive impairment compared to stable CN sub-
jects (p = 0.008), while MMSE scores were lower in the
former (p = 0.006). No significant alterations in the plasma
iron or heme proteins were observed in individuals
remaining stable or showing disease progression (Table 4).
Relationship between plasma proteins and neuroimaging/
cognitive measures in CN individuals
Multiple regression modeling of brain amyloid deposition
in CN subjects demonstrated lower levels of transferrin
(β = − 0.324, p = 0.0003) and ceruloplasmin (β = − 0.142,
p = 0.067), but higher levels of HPX (β = 0.408, p = 3.34 ×
10−4) were associated with increased amyloid deposition
(Fig. 2a). The left hippocampal volume was negatively cor-
related to ceruloplasmin (β = − 0.167, p = 0.052) and Hbβ
(β = − 0.277, p = 0.051) but positively correlated to hemo-
pexin (β = 0.143, p = 0.087) and Hbα (β = 0.271, p = 0.059),
but failed to reach significance (Fig. 2b). Meanwhile,
higher levels of transferrin (β = 0.145, p = 0.042) and Hbα
(β = 0.217, p = 0.098) but lower levels of Hbβ (β = − 0.242,
p = 0.065) were associated with a larger gray matter vol-
ume (Fig. 2c), which did not yield significance. Linear re-
gression modeling with MMSE score as the dependent
variable in CN subjects revealed augmented levels of
transferrin (β = 0.312, p = 0.010) associated with better
performance on the MMSE (Fig. 3a). Lastly, hemopexin
was negatively correlated to the CDR score (β = − 0.202,
p = 0.016; Fig. 3b) and CDR sum of boxes (β = − 0.198,
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p = 0.018; Fig. 3c). However, the latter did not pass the
FDR-corrected p value threshold for significance.
Association between heme and iron proteins in CN stable
and progression groups
To explain the differences in association between
heme and iron proteins, partial correlation analysis
was performed and illustrated as a heatmap with dif-
ferent association profiles in CN subjects remaining
stable and those progressing to become cognitively
impaired (Fig. 4). In the stable population, higher
levels of ceruloplasmin were associated with elevated
levels of HPR (r = 0.422, p = 3.523 × 10−6), Hbα (r =
0.245, p = 0.008), Hbβ (r = 0.191, p = 0.044, did not
reach FDR-corrected significance), and hemopexin
(r = 0.380, p = 3.502 × 10−5), but this pattern of associ-
ation was absent in the progression group. Also, ceru-
loplasmin was positively associated with haptoglobin
in the stable group (r = 0.222, p = 0.019) but did not
pass the FDR-corrected significance threshold. Fur-
ther, transferrin was positively associated with hapto-
globin (r = 0.454, p = 4.939 × 10−7) and HPR (r = 0.467,
p = 2.156 × 10−7) in the stable group but not signifi-
cant in the progression cohort. In the progression
group, transferrin was negatively correlated to Hbδ
but did not reach significance (r = − 0.440, p = 0.052).
Table 1 Baseline demographic and clinical characteristics of CN, MCI, and AD subjects
CN MCI AD p value
n – 144 AIBL, 94 KARVIAH 21 25 NA
Age Years (s.d.) 75 (7.362) 75 (6.226) 71 (9.072) 0.170
Female n (%) 105 (44%) 9 (43%) 13 (52%) 0.743
APOE-ɛ4 +ve n (%) 75 (32%) 10 (48%) 18b (72%) 1.46 × 10−4
PIB-PET# SUVR (s.d.) 1.425 (0.033) 1.853a (0.089) 2.374b,c (0.086) 3.224 × 10−20
MRI hippocampus (right, cm3)# Mean (s.d.) 3.102 (0.030) 2.970 (0.106) 2.858b (0.107) 0.008
MRI hippocampus (left, cm3)# Mean (s.d.) 3.200 (0.031) 3.142 (0.108) 3.075b (0.109) 3.600 × 10−5
MRI gray matter (cm3)# Mean (s.d.) 671 (4.611) 694 (16.207) 633b,c (16.316) 0.029
MRI white matter# (cm3) Mean (s.d.) 437 (4.514) 438 (15.866) 449 (15.973) 0.660
MMSE Mean (s.d.) 28.592 (0.119) 27.027a (0.388) 20.686b,c (0.382) 9.453 × 10−54
CDR scores# Mean (s.d.) 0.027 (0.013) 0.493a (0.036) 0.827b,c (0.035) 9.139 × 10−56
CDR sum of boxes# Mean (s.d.) 0.039 (0.045) 1.325a (0.134) 4.163b,c (0.125) 3.384 × 10−73
ANCOVA models adjusted for age, sex, and APOEε4 genotype. The mean and standard deviation (s.d.) are presented in the table with false discovery rate
correction set at 5%
aCN vs MCI
bCN vs AD
cMCI vs AD
#AIBL group only
Table 2 Baseline levels of plasma proteins involved in iron and heme metabolism in CN, MCI, and AD individuals
Plasma proteins CN MCI AD p value
Ceruloplasmin Mean (s.d.) − 0.001 (0.004) 0.002 (0.013) 0.003 (0.012) 0.867
Transferrin Mean (s.d.) 0.000 (0.006) − 0.008 (0.019) 0.003 (0.0170 0.698
Haptoglobin Mean (s.d.) 0.003 (0.007) − 0.025 (0.025) − 0.007 (0.023) 0.551
Haptoglobin-related protein Mean (s.d.) 0.002 (0.008) − 0.019 (0.027) − 0.007 (0.024) 0.787
Hemopexin Mean (s.d.) − 0.003 (0.006) − 0.016 (0.020) 0.037 (0.018) 0.059
Hemoglobin alpha 1 subunit Mean (s.d.) − 0.009 (0.012) − 0.019 (0.039) 0.078 (0.036) 0.103
Hemoglobin beta subunit Mean (s.d.) − 0.017 (0.012) 0.019 (0.041) 0.116b (0.038) 0.001
Hemoglobin delta subunit Mean (s.d.) − 0.013 (0.012) 0.021 (0.040) 0.086b (0.037) 0.036
CD163 Mean (s.d.) 0.004 (0.01) − 0.002 (0.034) 0.007 (0.031) 0.886
LRP1 Mean (s.d.) 0.008 (0.019) − 0.077 (0.064) − 0.008 (0.059) 0.424
ANCOVA models adjusted for age, sex, and APOEε4 genotype. The mean and standard deviation (s.d.) are presented in the table with false discovery rate
correction set at 5%
Units of measurement = a.u
aCN vs MCI
bCN vs AD
cMCI vs AD
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Further associations were observed in CN individuals
with stable cognition including higher haptoglobin levels
which were associated with augmented levels of hemo-
pexin (r = 0.402, p = 1.108 × 10−5) and CD163 (r = 0.321,
p = 5.565 × 10−4). On the contrary, CN subjects showing
progression to cognitive impairment showed negative cor-
relation between haptoglobin and CD163 levels (r = −
0.437, p = 0.054) but did not reach significance. Mean-
while, HPR was positively correlated to the hemopexin
(r = 0.539, p = 8.389 × 10−10) only in the stable population.
Both the Hbβ and Hbδ subunits were positively associated
with hemopexin (r = 0.205, p = 0.030; r = 0.208, p = 0.028
respectively) but did not surpass the FDR-corrected
significance threshold. Also, Hbβ and Hbδ subunits were
negatively associated with CD163 only in the stable group
(r = − 0.284, p = 0.002; r = − 0.257, p = 0.006). Hbα was as-
sociated with Hbβ and Hbδ in the stable (r = 0.841, p =
3.643 × 10−31; r = 0.839, p = 6.994 × 10−31) and progression
groups (r = 0.835, p = 4.701 × 10−6; r = 0.811, p = 0.141 ×
10−5). Similarly, Hbβ demonstrated significant correlation
to Hbδ in the stable group (r = 0.946, 1.218 × 10−55) and
progression group (r = 0.885, p = 2.196 × 10−7).
Discussion
AD causes a global disease burden involving failure of
neuroprotective mechanisms leading to altered heme/
Fig. 1 Modeling the association of plasma ceruloplasmin, transferrin, hemopexin, hemoglobin (Hb) α1, Hbβ, Hbδ, haptoglobin, haptoglobin-
related protein (HPR), cluster of differentiation (CD) 163, and low-density lipoprotein receptor-related protein 1 (LRP1) with a brain amyloid
deposition, b gray matter volume (GM Vol), c mini-mental state examination (MMSE), and d clinical dementia rating scale (CDR) score, in
cognitively normal, mild cognitive impairment, and Alzheimer’s disease, in the AIBL cohort. The models included age, sex, APOEε4 genotype, and
diagnosis as covariates. The standardized coefficient (β) and p values were stated: significant values that survive the false discovery rate correction
set at 5% are highlighted in yellow
Table 3 Baseline demographic and clinical characteristics of CN individuals remaining stable and individuals showing progression to
cognitive impairment (AIBL cohort)
Stable Progression p value
n – 115 23 NA
Age Years (s.d.) 72 (0.670) 72 (1.539) 0.761
Female n (%) 61 (53%) 9 (39%) 0.407
APOE-ɛ4 +ve n (%) 39 (34%) 13 (57%) 0.044
Brain amyloid deposition PET SUVR (s.d.) 1.35 (0.03) 1.62 (0.08) 0.008
MRI hippocampus (right, cm3) Mean (s.d.) 3.12 (0.03) 3.08 (0.07) 0.823
MRI hippocampus (left, cm3) Mean (s.d.) 3.22 (0.03) 3.17 (0.06) 0.642
MRI gray matter (cm3) Mean (s.d.) 674 (4.69) 668 (10.69) 0.633
MRI white matter (cm3) Mean (s.d.) 436 (5.099) 441 (11.049) 0.666
MMSE Mean (s.d.) 28.895 (0.114) 28.127 (0.248) 0.006
CDR scores Mean (s.d.) 0.024 (0.010) 0.021 (0.022) 0.893
CDR sum of boxes Mean (s.d.) 0.035 (0.017) 0.020 (0.037) 0.719
ANCOVA models adjusted for age, sex, and APOEε4 genotype. The mean and standard deviation (s.d.) are presented in the table with false discovery rate
correction set at 5%
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iron dyshomeostasis and oxidative stress-mediated neu-
rodegeneration [47]. In keeping with the theme of heme
dyshomeostasis [48], in this study, we found significantly
increased plasma levels of Hbβ subunit in AD compared
to CN individuals. A trend was apparent where lower
Hbα and higher levels of Hbδ were associated with in-
creased brain amyloid deposition. How Hb or its metab-
olites pass the blood-brain barrier remains to be fully
understood. It has been posited that increased perme-
ability of the blood-brain barrier early in the disease
process may increase Hb concentration in the brain
vasculature and explain the higher prevalence of cerebral
amyloid angiopathy in AD [49, 50]. Further, increased
Hb in the brains of human and transgenic mouse models
of AD has been suggested to induce astrocytic fatigue,
enabling pathogenesis mediated by Aβ [48, 49]. This is
in congruence with our finding of a trend of lower
plasma levels of Hbα associated with increased brain
amyloid deposition.
Blood from healthy aged humans (29–51 years) and 8-
week old young adult mice showed that Hbα subunits
can efficiently remove hydrogen peroxide to prevent
Table 4 Baseline levels of plasma proteins implicated in iron and heme metabolism in CN individuals remaining stable and
individuals showing progression to cognitive impairment (AIBL cohort)
Plasma proteins Units Stable Progression p value
Ceruloplasmin Mean (s.d.) 0.001 (0.006) 0.001 (0.014) 0.867
Transferrin Mean (s.d.) 0.003 (0.008) 0.007 (0.019) 0.794
Haptoglobin Mean (s.d.) 0.005 (0.01) 0.025 (0.024) 0.458
Haptoglobin-related protein Mean (s.d.) 0.003 (0.011) 0.036 (0.025) 0.216
Hemopexin Mean (s.d.) 0.000 (0.010) − 0.012 (0.022) 0.844
Hemoglobin alpha 1 subunit Mean (s.d.) − 0.014 (0.016) 0.042 (0.036) 0.067
Hemoglobin beta subunit Mean (s.d.) − 0.024 (0.016) 0.015 (0.037) 0.263
Hemoglobin delta subunit Mean (s.d.) − 0.020 (0.016) 0.024 (0.037) 0.204
CD163 Mean (s.d.) 0.009 (0.015) − 0.012 (0.035) 0.465
LRP1 Mean (s.d.) 0.007 (0.026) 0.028 (0.060) 0.901
ANCOVA models adjusted for age, sex, and APOEε4 genotype. The mean and standard deviation (s.d.) are presented in the table with false discovery rate
correction set at 5%
Units of measurement = a.u
Fig. 2 Modeling the association of plasma ceruloplasmin, transferrin, hemopexin, hemoglobin (Hb) α1, Hbβ, Hbδ, haptoglobin, haptoglobin-
related protein (HPR), cluster of differentiation (CD) 163, and low-density lipoprotein receptor-related protein 1 (LRP1) with a brain amyloid
deposition, b left hippocampal volume (Hip Vol (L)), and c gray matter volume (GM Vol) in the AIBL cohort. The models included age, sex,
APOEε4 genotype, and conversion status as covariates. The standardized coefficient (β) and p values were stated: significant values that survive
the false discovery rate correction set at 5% are highlighted in yellow
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oxidative degradation of Hb, and its ability to scavenge
is overtly enhanced in the presence of reduced pyridine
nucleotides [20]. Previously, it has been documented
that Hb and heme may help to suppress Aβ-mediated
inflammatory activation of astrocytes [49]. Although we
report correlation, not causation, the varying association
between different subunits leads us to hypothesize that
Hb subunits may modify Aβ-mediated toxicity and
ameliorate oxidative stress, probably in divergent ways.
This is supported by our finding of an increasing trend
Fig. 3 Modeling the association of plasma ceruloplasmin, transferrin, hemopexin, hemoglobin (Hb) α1, Hbβ, Hbδ, haptoglobin, haptoglobin-
related protein (HPR), cluster of differentiation (CD) 163, and low-density lipoprotein receptor-related protein 1 (LRP1) with a mini-mental state
examination (MMSE), b clinical dementia rating scale (CDR) score, and c clinical dementia rating sum of boxes (CDR SB), in the AIBL cohort. The
models included age, sex, APOEε4 genotype, and diagnosis as covariates. The standardized coefficient (β) and p values were stated: significant
values that survive the false discovery rate correction set at 5% are highlighted in yellow
Fig. 4 Partial correlation analysis adjusted for age, sex, and APOEε4 genotype conducted separately in cognitively normal AIBL individuals
remaining stable and showing progression to cognitive impairment. The scale bar represents the correlation coefficient (R2) and false discovery
rate-corrected significance set at 5% represented by *p < 0.015, **p < 0.009, and p < 0.005***. Cp, ceruloplasmin; TF, transferrin; HP, haptoglobin;
HPR, haptoglobin-related protein; Hb, hemoglobin subunits (α, β, δ); HPX, hemopexin; CD163, cluster of differentiation 163; LRP1, low-density
lipoprotein receptor-related protein
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of Hbα associated with increased hippocampal volume
in CN individuals (adjusted for conversion status), but
the relationship was found to be the converse for Hbβ,
suggesting perturbations in heme biology is an early
event in AD pathogenesis (Fig. 5).
Interestingly, our data showed that increased brain
amyloid deposition was associated with higher levels of
plasma HPX in the whole cohort, but higher HPX was
associated with a lower CDR score in CN individuals
(adjusted for conversion status). HPX co-partners with
haptoglobin to bind heme with high affinity and confers
protection against free heme-mediated toxicity, main-
taining iron homeostasis via recycling of heme iron [28].
HPX knockout mice studies have further substantiated
its role as an effective heme/iron scavenger [32]. We ob-
served a significant positive association between HPX
and haptoglobin and a trend for Hbβ and Hbδ, only in
CN individuals who remained stable, but this association
was absent in those that progressed to cognitive impair-
ment. This suggests that under normal conditions, HPX
scavenges and detoxifies heme, but under pathological
conditions such as in AD, Aβ disrupts HPX binding to
heme through formation of Aβ-heme complex, thereby
promoting peroxidase activity and accentuating oxidative
stress [51–54]. The peroxidase activity of Aβ-heme com-
plexes have been shown to induce peptide dimer forma-
tion, which in turn enhance Aβ fibrillization [55]. The
formation of Aβ-heme complex can decrease heme bio-
availability of heme, in effect, inducing functional heme
deficiency [51]. The excessive build-up of heme derived
from Hb has been shown to aggravate tau aggregation
via the N-terminal free-amines, prolonging peroxidase
activity and perpetuating neuronal oxidative stress [56].
Unexpectedly, increased HPX levels correlated with a
trend of a decrease in MMSE. However, elevated HPX
levels may not reflect increased function as HPX may
well be oxidized/inactivated under pathological condi-
tions operant in AD [57, 58]. The only known HPX-
heme complex receptor has been identified as LRP1
(also known as CD91), which is expressed in several cell
types including macrophages, hepatocytes, neurons, and
syncytiotrophoblasts [59] and is responsible for mediat-
ing HPX-heme internalization into cells for heme de-
toxification. We did not observe a significant association
between LRP1 and HPX in the CN stable or progression
group. However, the role of LRP1 expressing cell types
needs to be elucidated alongside putative contribution of
alternative receptors for HPX-heme clearance.
Under physiological conditions, haptoglobin binds
avidly to Hb and at macrophages, following binding to its
cognate receptor, CD163, the complex is endocytosed,
thereby mediating heme and iron homeostasis [28, 60]. In
our dataset, higher levels of haptoglobin were associated
with increased levels of CD163 in stable CN individuals
but demonstrated a trend of negative association in those
showing progression to cognitive impairment. This could
imply in the latter CN individuals, uptake of the
haptoglobin-Hb complex by CD163 is inhibited, allowing
aberrant heme signaling to increase redox-active iron,
which precipitates oxidative stress in AD. The chaperone,
haptoglobin, has also been shown to be susceptible to oxi-
dation which hinders its scavenging ability, and in AD,
Fig. 5 Schematic to summarize the main findings of the study. Hemoglobin (Hb) α and β derived heme is scavenged by hemopexin (HPX)
complemented by its co-partner haptoglobin (HP) to form HPX-heme complex. Heme contributes to redox-active iron which is loaded onto
transferrin (Tf) with the help of ceruloplasmin (Cp) to maintain iron homeostasis. In the presence of increasing Alzheimer’s pathology, augmented
levels of Hbβ leads to excess free heme, which in the presence of a dissociation between HPX and HP impairs the heme detoxifying system. This
enables β-amyloid (Aβ) to readily form complexes with heme to increase the redox-active iron pool. Since higher levels of Aβ were associated
with lower levels of Tf, the ability of Tf to circulate iron is compromised. The impaired homeostasis of iron leads to enhanced oxidative stress,
which contributes to neurodegeneration and progression of Alzheimer’s pathology
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enabling Aβ to readily bind heme, further exacerbating
Aβ-induced toxicity [61, 62].
Consistent with previous studies, we did not find sig-
nificant alterations in plasma transferrin levels in the CN
versus the disease groups. Nevertheless, we demonstrate
lower levels of transferrin are associated with augmented
brain amyloid uptake. This could particularly be prob-
lematic in AD, where deficiency of iron loading into
transferrin [7] may enable non-transferrin-bound iron to
detrimentally contribute to the labile iron pool, which
could help propagate Aβ-toxicity. Our finding of in-
creased transferrin levels being associated with increased
hippocampal volumes and improved MMSE scores un-
derscores the importance of the role of transferrin to
bind iron in a safe and redox-inactive form to distribute
elsewhere. The relationship between plasma and brain
iron needs to be established; one could hypothesize that
the decreases in plasma iron [7, 9] is due to increased
partitioning of iron into the brain in AD [63]. Macro-
phages have been suggested to require the ferroxidase
activity of ceruloplasmin to load iron onto transferrin.
We did not find an increase in ceruloplasmin levels, but
ceruloplasmin concentration is not a measure of its ac-
tivity since oxidation of ceruloplasmin can impair its fer-
roxidase activity [64] and inhibit iron loading onto
transferrin in AD [8]. One limitation of the study was
that we did not investigate protein activities, which
could be a useful corollary study. We performed correl-
ation analysis to evaluate the relationship between heme
and iron proteins, which does not necessarily equate to
causation; hence, future experiments should be directed
at identifying causal relationships. In summary, it would
be beneficial to understand the expression levels/activity
of heme and iron proteins in the plasma, CSF, and tis-
sues of the same subjects to more fully understand heme
and iron distributions between various compartments
and elucidate the mechanistic interplay.
Perturbed iron homeostasis is a feature of several neu-
rodegenerative diseases including AD, Parkinson’s dis-
ease, frontotemporal dementia, and amyotrophic lateral
sclerosis. We did not study the impact of tau which cor-
relates better with disease progression than Aβ [65] or
the contribution of α-synuclein, tau, and TDP43 path-
ologies in the present study, as these pathologies are
prevalent in 50% and 30% of AD patients respectively
[66]. We predict that these proteins may affect levels of
heme and iron proteins, as iron is required for seeding
and aggregation of tau [67], of α-synuclein [68], and, in-
directly, of TDP43 [69, 70]. We have recently provided
evidence to support the presence of a recently discov-
ered iron-dependent cell death, ferroptosis, in AD [71].
Iron chelation has shown promise against AD and PD in
preclinical studies and clinical trials and has therapeutic
potential to extinguish iron-dependent ferroptosis, a
mechanism proposed to contribute to neurodegenera-
tion [67]. With relevance to AD, longitudinal studies have
shown iron burden to be associated with pronounced in-
crease in rate of cognitive decline in Aβ-positive individuals
[63, 72, 73]. Moreover, heme/iron accumulation is preferen-
tially observed in AD affected regions of the brain including
parietal cortex, motor cortex, and hippocampus [19, 74–78].
Interestingly, accumulation of tau neurofibrillary tangles is
associated with heme oxygenase-1 induction which may fur-
ther accentuate oxidative stress via release of redox-active
iron from heme catabolism [79–81]. We did not perform
[18F]FDG-PET to measure glucose metabolism but predict
that heme/iron homeostatic proteins would be closely associ-
ated with hypometabolism in AD. Whether iron is associated
with region-specific effects of neurodegenerative diseases and
how it interacts with different pathological proteins/aggre-
gates would be an exciting avenue to explore.
Importantly, heme is derived from Hb, which is enriched
in red blood cells [15]. In AD, erythrocytes have been found
to contain more surface-bound IgG displaying augmented
proteolysis and ensuing oxidative stress, which may trigger
their lysis and a subsequent increase in free Hb fragments
[82, 83]. Together with the reduced heme scavenging poten-
tial apparent in AD, this may in part explain our finding of
increased plasma Hbβ in AD and the varying associations we
observed. However, longitudinal studies are warranted to
simultaneously temporally stage CSF Hb during the progres-
sion of AD to understand brain-periphery relationships.
Detailed mechanistic studies are required to understand
post-translational modifications of Hb and their associations
with Aβ and tau. Also, different neuronal cell lineages can be
transfected to upregulate or downregulate Hbα and Hbβ, to
test their vulnerability to Aβ and tau toxicity. In transgenic
mouse models of AD, cell type-specific (neuron, microglia,
and astrocytes) deletions and overexpression of Hb chains
can be performed to assess whether these modifications will
alleviate or aggravate the disease burden.
Conclusion
In conclusion, heme (iron) dyshomeostasis appears to be
a feature of AD. The causal relationship between heme/
iron metabolism and AD warrants further investigation.
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